McKesson agrees to buy Precision Medicine Group in $2.25B deal
Money MovesDrug distributor deepens oncology pivot with clinical research and commercialization services
Yesterday: McKesson signs Precision Medicine dealNew here? Follow stories to track developments over time. Create a free account to get updates when stories you care about change.
Overview
Updated 1 hour agoThe largest US drug distributor, McKesson, agreed on August 25 to buy Precision Medicine Group for $2.25 billion. Precision runs clinical trials, biomarker labs, and payer-negotiation services for biotechnology and pharmaceutical companies.
The purchase is McKesson's biggest bet yet on its two-year pivot from shipping pills to selling oncology services and data. It places the company inside the drug-development pipeline, where margins run far higher than distribution.
Why it matters
As cancer drugs target specific mutations, pharma money is shifting from distribution to clinical services; McKesson just bought a bigger seat at that table.
Questions about this story
Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.
No questions yet — be the first to ask.
Key Indicators
Voices
Curated perspectives — historical figures and your fellow readers.
Play
Exploring all sides of a story is often best achieved with Play.
Higher or Lower
A number from this story, against one from elsewhere in the news — guess which is bigger, then keep the chain going. 5 rounds, 3 strikes; a miss costs a strike and resets your streak.
Keyboard: ↓/L lower · ↑/H higher
0 points — sign up to put that on the leaderboard.
Connections
Sixteen names from the news. Find the four hidden groups of four. Four mistakes max.
Sign up to keep a daily streak — a new puzzle lands every day.
Exit debate?
Your progress in this debate will be lost.
- 1 Two AI personas square off on this story.
- 2 You predict who'll win each round — correct picks earn XP.
- 3 One crossfire question is yours to fire. Pick it carefully.
Couldn't generate a topic
Select Your Champions
Choose one persona for each side of the debate
DEBATE TOPIC
Choose personas with different perspectives for a more dynamic debate.
Select debater for this side:
No debate personas available right now.
Select debater for this side:
No debate personas available right now.
Who's Got This Round?
Make your prediction before the referee scores
The referee scores both sides on
Round Results
Set the Crossfire
Pick the question both personas must answer in the final round
Debate Oracle! You called every round!
Sharp Instincts! You know your debaters!
The Coin Flip Strategist! Perfectly balanced!
The Contrarian! Bold predictions!
Inverse Genius! Try betting the opposite next time!
XP Breakdown
Prediction History
People Involved
Organizations Involved
The largest US drug distributor, restructuring around oncology and specialty care.
Bethesda-based services firm helping biotech and pharma companies develop and launch drugs.
US private equity firm that has owned Precision Medicine since 2020.
Timeline
2012 August 2026
-
McKesson signs Precision Medicine deal
Latest AcquisitionMcKesson signs a $2.25 billion agreement to buy Precision Medicine Group.
-
McKesson sells med-surgical stake
DivestitureMcKesson sells a minority stake in its medical-surgical unit to Apollo for $1.25 billion.
-
Prism Vision deal closes
AcquisitionMcKesson closes the Prism Vision acquisition, adding ophthalmology services.
-
McKesson targets Prism Vision
AcquisitionMcKesson announces an $850 million deal for 80% of Prism Vision Holdings.
-
Blackstone takes majority stake
Ownership changeBlackstone buys a majority stake in Precision at a $2.3 billion valuation.
-
Precision Medicine Group founded
FoundingEthan Leder and Mark Clein launch the company in Bethesda, Maryland.
Historical Context
3 moments from history that rhyme with this story — and how they unfolded.
LabCorp acquires Covance (2015)
LabCorp agreed in late 2014 to buy Covance for about $6.1 billion in cash and stock, pairing its diagnostic-testing network with Covance's clinical trial services. The combined company sold drugmakers lab tests tied to their clinical studies.
The deal closed in March 2015 and made LabCorp a leading provider of clinical trials testing.
It showed a health services company could attach drug-development services to its core business and win higher-margin work.
Same logic driving McKesson: fold clinical research services into an existing healthcare services base.
Thermo Fisher acquires PPD (2021)
Thermo Fisher agreed in April 2021 to buy clinical research firm PPD for about $17.4 billion, its largest acquisition ever. The deal combined Thermo's scientific tools with PPD's contract research organization.
Closed in December 2021, adding billions in annual contract research revenue.
Reinforced that scale matters in outsourced drug development and commercialization.
Shows the size and consolidation of the clinical services market McKesson is entering.
Icon acquires PRA Health Sciences (2021)
Dublin-based Icon agreed in February 2021 to buy rival PRA Health Sciences for about $12 billion, creating one of the world's largest clinical research organizations.
The deal closed in July 2021.
It was part of a wave of contract research consolidation as pharma outsources more trial work.
Precision Medicine's CRO unit competes in the same consolidating market McKesson now enters.
